



THC GLOBAL GROUP LIMITED (ASX:THC) TO BE RENAMED
EPSILON HEALTHCARE LIMITED

Diversified Healthcare and Pharmaceuticals

A healthcare company with diversified investments in healthcare, pharmaceuticals, and medicinal cannabis actively operating in Australia and Canada



Disclaimer

The material in this presentation (Material) is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security in THC Global Group Limited (THC) (ACN 614 508 039) nor does it form the basis of any contract or commitment. In the event that an offer, invitation or recommendation to subscribe for, or purchase any security in THC is made in the future, an Offer Document will be made available in relation to the same. If and when the Offer Document becomes available it may be downloaded from the THC's website at thc.global. At that time, any person wishing to make an investment in THC must consider the Offer Document in deciding whether to acquire the security and must complete the application form that will be in or will accompany the Offer Document.

THC makes no representation or warranty, express or implied, as to the accuracy, reliability or completeness of this Material. THC, its directors, employees, agents and consultants shall have no liability, including liability to any person by reason of negligence or negligent misstatement, for any statements, opinions, information or matters, express or implied, arising out of, contained in or derived from, or for any omissions from this material except liability under statute that cannot be excluded.

Statements contained in this Material, particularly those regarding possible or assumed future performance, costs, dividends, production levels or rates, prices, resources, reserves or potential growth of THC, industry growth or other trend projections are, or may be, forward looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of factors. The principal important risk factors that could cause THC's actual performance and future events and actions to differ materially from such forward-looking statements, include, but are not limited to, continuing volatility in the capital or credit markets and other changes in the securities and capital markets, changes in market prices of THC's investments, the occurrence of one or more catastrophic events, such as an earthquake, hurricane, or act of terrorism, changes in laws or regulations, changes in income tax laws, and changes in general economic and market factors that affect the prices of securities or the industries in which it does business.

This Material includes certain statements, estimates and projections that rely upon various assumptions. Those assumptions may or may not prove to be correct. The Material does not purport to contain all the information that a prospective investor may require. The information may not be appropriate for all persons, and it is not possible for THC to have any regard to the investment objectives, financial situation and particular needs of each recipient who reads or uses this information.

Healthcare and High Value Pharmaceuticals



Pharma Manufacturing Facility

High volume EU and TGA GMP bio-floral extraction and pharmaceutical manufacturing facility in Southport, Qld



Australian Cultivation Facility

Licensed and permitted hydroponic cannabis cultivation and research facility in Bundaberg, Qld



New Pharma E-Commerce Platform

Medimar platform to connect patients, prescribers, and pharmacies with unique ecommerce distribution offering



Toll and Contract Manufacturing Focus

Moving towards offering toll and contract manufacturing over own production to increase volume



Niche and Unique Cannabis Products

Launching 'Uno' as a unique brand of cannabis products taking advantage of manufacturing expertise



Achieved Reduced Run Rate

Significant run rate reductions identified over strategic review saving over \$3m in annualised run rate



Telehealth Clinics

Tetra Health offering a telehealth clinic for medicinal cannabis with large prescriber and patient network



Equipment and Cultivation Solutions


Canada based hydroponics equipment distributor with turnkey cultivation solutions offering including nursery



Sustainable Revenue Focus

Revised global focus towards sustainable revenue with faster paths to profitability utilising existing assets

Global Cannabis Business





Strategic & Financial Review



Strategic Changes

Healthcare Focussed

Rebranding the parent company to Epsilon Healthcare as part of a broader shift into healthcare and pharmaceuticals

Transition to Toll Manufacturing

Realising value of the Company's significant GMP manufacturing capability by pivoting to high value pharmaceuticals manufacture

Reviewing Australian Cannabis Cultivation

Reviewing cultivation operation viability, with +\$1m annual run rate savings identified and actioned during assessment of other options for future cannabis cultivation in Australia

Launching the Medimar Platform

Offering a unique end to end e-commerce platform for cannabis in Australia, utilising Southport Facility as a distribution hub

Refocused Medicines Production

Tapering production of 'CanndeoCare' and launching 'Uno' as a new niche market cannabis brand including Vapes and other medicine forms

Material Operating Costs Reduction

Significant operating cost savings realised through review of existing activities and proposed new business units

Capital & Financial Overview



Reduced Run Rate

Identified and implemented over \$3m in annualised run rate savings, expected to be fully realised over Q4 2020



Reviewing Non-Core Activities

Reviewing future of Australian cannabis cultivation, and exploring divestment opportunities for Canadian cannabis assets



Focus on Sustainable Revenue

Revised approach to focus on sustainable revenue growth, particularly with respect to Australian cannabis activities



Tetra Continues Growth

Achieved 28% growth in active patients in Q3 over Q2 2020, high renewal rates for active patients, and operates profitably



Cultivation Solutions Outperforms

Canadian operations YTD to Sept 2020 has exceeded 2019 FY Revenue – A\$4.9 million*

RECENT FINANCIALS

Cash 30 September	\$7.26 million
Q3 Receipts from Customers Appendix 4C	\$2.12 million
Q3 Net Cash from Operating Activities Appendix 4C	-\$2.52 million

Refer to Q3 2020 Appendix 4C released on 30 October 2020 for more information.

* Unaudited Figure

Corporate Rebranding



Healthcare and Pharmaceuticals

Change of name and branding supports a move towards patient led healthcare and high value pharmaceutical production

Broader than Cannabis

Moving away from reference to "THC" given perception that "THC" is related to the recreational cannabis market

Shareholder Approval at EGM

Name and ASX code change will require shareholder approval at an EGM proposed to be held in December 2020



Australian Medicinal Cannabis and Pharmaceuticals

Pharma Manufacturing

PIVOTING TOWARDS TOLL MANUFACTURING

Moving away from operating as primarily an 'own brand' manufacturing facility and instead expanding into toll and contract manufacturing enables an increase in volume of throughput and delivers revenue whilst reducing per-unit production cost.

In discussion with a number of potential partners and expecting to progress to binding production agreements in the near term.



Scalable Production

Potential for production ramp up to support over 1 million patients per annum at existing facility enables discussions with global partners for high volume medicines manufacture



Broad Production Capability

Capable of both cannabis and non-cannabis extraction and medicines production, opening further markets to build production volumes or develop novel formulations



Full QC/QA Lab Onsite

On-site quality control and quality assurance lab reducing product testing and validation costs and enabling contract validation and testing for third parties as supplementary revenue source

Australian Cultivation

Outlook

- Reviewing value in continuing to cultivate own cannabis within Australia
- Temporary suspension of activities at Bundaberg Facility during review period resulting in annualised run rate saving of +\$1 million*

Strategy Options

- New Genetics: Recommence cultivation post sourcing new higher yielding plant genetics
- Identifying Partners: Taking advantage of existing facility with licences and permits to offer contract cultivation solutions saving partners time and cost in developing own facilities

Australian Assets

- Fully licenced and permitted hydroponic greenhouse for cannabis cultivation in Bundaberg, Queensland
- Ballina and other Australian cultivation projects to not proceed until after new strategy in place

* Unaudited Figure

Own Brand Medicines

CanndeoCare


- Production of CanndeoCare branded medicines to taper down over early 2021 in support of a primarily toll manufacturing based approach for the Southport Facility
- Exiting own production across wide SKU range will reduce perception that the Company is competing against its own toll manufacturing customers
- Toll manufacturing to deliver stronger revenue growth and faster pathway to profitable production

Project Uno

- 'Uno' to be launched as the Company's new brand for niche or unique cannabis medicines for Australian and export markets
- Targeting Australian launch of a high THC vape liquid for late 2020 followed by high CBD vape liquid
- 'Uno' products to also be marketed for export into New Zealand, Canada, and Europe


Medimar Platform

A proprietary end to end e-commerce platform for the ordering and dispensing of medicinal cannabis, reducing admin burden on prescribers and pharmacies, enabled by the Company's licenced distribution facility.



Prescribers

Reduces admin workload for prescribers and streamlines application processes



Pharmacies

Increases volume of sales and enables bulk purchasing and holding whilst reducing admin



Patients

Single point of contact for enquiries and ability to choose any pharmacy for dispatch




Distribution

Replaces existing high cost legacy pharma distributors and reduces distribution time

Medimar Platform

REGISTRATIONS COMMENCE FOR PRESCRIBERS, PHARMACIES, AND SUPPLIERS BY MID-NOV WITH FULL LAUNCH EXPECTED IN JANUARY 2021

medimar.com.au





Tetra Health

TELEHEALTH CLINIC SPECIALISING IN MEDICINAL CANNABIS

For patients, Tetra Health is an easy way to access medicinal cannabis through a network of telehealth physicians and with ongoing support from a team of nurses based in Australia.

For suppliers, Tetra Health is a high volume product clinic network prescribing over 60 products from many suppliers, with a valuable real-world patient data collection capability.

Large Prescriber Network

Tetra's prescriber network includes over 600 prescribing physicians with an even larger contact and referral database

Significant Growth

Number of active Tetra patients increased 28% in Q3 2020 over Q2 2020 and seeing high annual renewal rates for existing patients

In-Hospital Presence

Partnering with leading hospitals and clinic networks to offer an in-person patient experience, simplifying admin for doctors

Co-Branded Clinics

In negotiations to launch Tetra clinics within existing GP and specialist clinics, to support patients & doctors in accessing cannabis

Supporting Patients


Leader in affordability over an annual period with service including ongoing nursing support & follow up doctor consultations

Clinical Trial Support

Tetra's data collection and nursing support have made them a reliable partner for conducting observational trials in Australia

Australian Cannabis Value Chain

Control of entire value chain from plant material, through to end distribution to patients or export markets with revenue touchpoints at each step



Plant Material Access

Ability to be a contract cultivator at Bundaberg Facility, process plant material supplied by client, or source raw materials from other parties for clients

GMP Manufacturing

World-class high-volume TGA and EU GMP extraction and manufacturing facility with onsite labs and finishing capability

Distribution Pathways

Ability to hold and distribute medicines using the Medimar Platform or prescribe through Tetra Health in addition to acting as exporter using granted wholesale and export licences



Hydroponics and Canadian Cannabis

Hydroponics Equipment



Continued Revenue Growth

Revenue for the year to the end of Sept 2020 for CMP has exceeded total FY2019 revenue, achieving A\$4.9 million. Further, revenue has grown 74% in Q3 2020 vs Q3 2019.

Expanding Distribution

In addition to export opportunities, the Company is additionally expanding across Canada, with a 3PL on the east coast.

Diversified Product Range

CMP range includes over 1,000 SKUs in equipment and supplies. CMP additionally granted medical device licence and is entering medical supplies sales.

Servicing a Large Market

The home grower and small commercial grower sectors in Canada continue to expand, increasing CMP's target market.

Cannabis Services and Retailing



GROW.

Turnkey Solutions

Providing turnkey cultivation solutions under the Canndeo brand combining equipment, supplies, and advisory services

Additional Revenue

Advisory and solutions provider, Canndeo Fulfilment, achieved Q3 revenue of A\$135k and is profitable*

Advisory Services

Advisory services offered by Canndeo Fulfilment are targeted towards new cultivators and small scale operators

Licenced for Retail

Health Canada licence granted for Medical Sales Without Possession enabling commencement of a cannabis sales business

Nursery Facility Build Out

In final stage of build out with cultivation and processing licence pending for a new cannabis nursery in Vancouver, BC

Nursery Revenue

B2B and B2C sales of cannabis clones from nursery to commence shortly with potential to expand into second east coast site

* Unaudited Figure



Corporate Structure

Global Management Team



Steven Xu

Non-Exec Chairman



Alan Beasley

Non-Exec Deputy Chairman



Jarrod White

Interim Group Chief Executive
Officer & Chief Financial Officer



Sonny Didugu

Group Chief Operating Officer
& Joint Company Secretary



Laura Harvey

Chief Operating Officer
Canadian Operations



Angela Macquire

Chief Operating Officer
THC Pharma



Diandra Phipps

Chief Operating Officer
Tetra Health



Philip Leighfield

Joint Company Secretary

Capital & Financial Information

KEY INFORMATION

ASX code	ASX:THC
Listing Date	May 2017
GICS Classification	Pharmaceuticals, Biotechnology & Life Science
Share Price	\$0.23
Market Cap	\$41.04 million
Shares on issue	178,456,949
Shareholders	9,358

RECENT FINANCIAS

Cash 30 September	\$7.26 million
Q3 Receipts from Customers Appendix 4C	\$2.12 million
Q3 Net Cash from Operating Activities Appendix 4C	-\$2.52 million

Refer to Q3 2020 Appendix 4C released on 30 October 2020 for more information.

Share capital information as at 30 October 2020.

THC Global Group (ASX:THC)

TO BE RENAMED

Epsilon Healthcare Limited

(Subject to approval)

Corporate Office
Suite 4102
Level 41 Australian Square
264-278 George Street
Sydney NSW 2000
Australia

Email us at
corporate@thc.global

Visit us at
thc.global

